Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group.
A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia. This study demonstrated a significant difference in birthweight and incidence of fetal growth retardation between treatment and placebo groups. No difference was demonstrated between aspirin and aspirin + dipyridamole patients.
Sureau
C
C
D000037:Abruptio Placentae / Q000209:etiology / Q000517:prevention & control*; D001241:Aspirin / Q000627:therapeutic use*; D001724:Birth Weight / Q000187:drug effects; D004176:Dipyridamole / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005313:Fetal Death / Q000209:etiology / Q000517:prevention & control*; D005317:Fetal Growth Retardation / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D011225:Pre-Eclampsia / Q000150:complications* / Q000188:drug therapy; D011247:Pregnancy
D004338:Drug Combinations; D004176:Dipyridamole; D001241:Aspirin